Novo Nordisk Eliminating 400 Jobs in R&D Restructuring – Genetic Engineering & Biotechnology News
‘Not Aimed at Reducing Cost Base’ Inchausti said the R&D restructuring was not aimed at reducing our cost base. On the contrary, our R&D to sales ratio in 2019 remains stable. Thomsen told Reuters the company expects to spend more on research and development this year than the DKK 14.014 billion ($2.199 billion) it spent…
Details